Europe PMC
open access
ADPKD as a Temporally Dynamic Disease: Implications for Biomarkers, Trial Design, and Therapeutic Targeting
Autosomal dominant polycystic kidney disease (ADPKD) has traditionally been conceptualized as a structurally progressive disease, with cyst growth driving loss of kidney function. This view has led to the widespread use of total kidney volume for risk stratification and clinical trial design. Howeve
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Efficacy of Tolvaptan on ADPKD Patients#1259528
- Challenges in Classification of PKD1 Missense Variation in Autosomal Dominant Polycystic Kidney Disease#619221
- Polycystic Kidney Disease Data Repository#1498142
- STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease#1060320
- Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease#1196962
Record · ID 1500315
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive